If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
== Treatment == Treatment of tea and toast syndrome is centered primarily around resolving hyponatremia. Treatment choice depends on the type of hyponatremia. Traditional treatment for hyponatremia depends on the volume load in the person. For those who are euvolemic (normal body volume load), fluid intake should be restricted. In those that are hypovolemic (low body volume load), give isotonic saline. In those that are hypervolemic (high body volume load), diuresis should be induced. Elderly patients may present in any of these volume states. However, "tea and toast" syndrome patients typically present euvolemic hyponatremia since their hyponatremia is caused by low solute intake. These patients must receive proper nutrition that is higher in protein and electrolyte intake. The Health and Medicine Division of the National Academies of Science, Engineering, and Medicine recommends that older adults improve their diet by consuming more fish, low-fat dairy products, and whole grains (such as fortified breakfast cereals). Older adults can also improve their diet by snacking on nuts and legumes as well as ensuring that they include fruit and vegetables at the center of their diet.
==== United States Champion; departure (1993–1994) ==== At Starrcade '93: 10th Anniversary in December 1993, Austin defeated Dustin Rhodes 2–0 in a two-out-of-three-falls match to win the WCW United States Championship. At Clash of the Champions XXVIII in August 1994, Austin lost the Championship to Ricky Steamboat. He was scheduled to face Steamboat in a rematch at Fall Brawl '94: War Games in September 1994; however, Steamboat was unable to wrestle due to a legitimate back injury and Austin was awarded the championship by forfeit. His second reign with the championship ended just five minutes later when he lost to Steamboat's replacement, Jim Duggan, in a match that lasted 35 seconds. Austin unsuccessful challenged Duggan for the championship at both Halloween Havoc in October 1994 and Clash of the Champions XXIX in November 1994. The influence of Hulk Hogan and the Hulkamania era was beginning to take hold in WCW, with vice president Eric Bischoff saying this was likely the reason Austin lost to Duggan, who had been a popular figure during that period of time. Around this time, Austin pitched a storyline idea to Bischoff in which it would be revealed that Austin was a family member of Hogan. The proposal was quickly turned down on account of Bischoff's belief that Hogan would not work with somebody such as Austin, who was not a proven name. Following Clash of the Champions XXIX, Austin was inactive while rehabilitating a knee injury, returning in February 1995.
Despite these conclusions, all researchers observed a degree of managerial activities among the groups they studied. All observed networks and a degree of persistence, and there may be utility in focusing on the identification of organizing roles of people and events rather than the group's structure. There may be three main approaches to understand the organizations in terms of their roles as social systems:
I am left with the impression that the attorneys in charge of the Labscam investigation ... seek to take far more credit for the overall success of the proceedings than is rightly due. Philadelphia-based SmithKline agreed to pay the government $325 million which is considered as one of the largest civil settlement ever in a whistle-blower lawsuit. The company settled after the government alleged it paid kickbacks to doctors, billed the government for laboratory tests not performed and committed other violations. SmithKline has denied the allegations, saying the violations were unintentional and the result of ambiguities in regulations and guidelines. When interest and payments to state Medicare funds were taken into account, the final settlement came to about $321 million. VanArtsdalen said Merena and the other whistle-blowers accounted for all but about $15 million of that total. The government failed to reach an agreement with litigants Merena and Grossenbacher on the amount that they would receive from the settlement agreement. The government maintained that Merena was entitled to approximately $10 million of the $65 million attributable to the non-"automated chemistry" claims and has paid Merena this amount. The government and the Spear relators have a proposed agreement that, if approved, will award the Spear relators 15% of the $13 million that the government attributed to a claim called the "CBC Indices" claim. The government previously agreed to pay the whistle-blowers a minimum of $9.7 million but only if they dropped claims to a larger portion.
=== Ion funnel === Ion funnels are RF devices which have been used for decades to focus ion currents into narrow beams. In PTR-MS they have been introduced in 2012 by Barber et al. when they presented a PTR-MS setup with a PTR reaction region incorporating an ion funnel. Although the focusing properties of the ion funnel improved the sensitivity of the setup by a factor of >200 (compared to operating in DC only mode, i.e. with the ion funnel turned off) for some compounds, the sensitivities of other compounds were only improved by a factor of <10. That is, because of the highly compound dependent instrumental response one of the main advantages of PTR-MS, namely that concentration values can be directly calculated, is lost and a calibration measurement is needed for each analyte of interest. Furthermore, with this approach unusual fragmentation of analytes has been observed which complicates interpretation of measurement results and comparison between different types of instruments even more. A different concept has been introduced by the company IONICON Analytik GmbH. (Innsbruck, AT) where the ion funnel is not predominantly part of the reaction region but mainly for focusing the ions into the transfer region to the TOF mass spectrometer. In combination with the above-mentioned method of controlling the ion chemistry this enables a considerable increase in sensitivity and thus also an improvement of the detection limit, while keeping the ion chemistry well-defined and thus avoiding problems with quantification and interpretation of the results.
Sources: en.wikipedia.org
The vacuum flask was designed and invented by Scottish scientist James Dewar in 1892 as a result of his research in the field of cryogenics and is sometimes called a Dewar flask in his honour. While performing experiments in determining the specific heat of the element palladium, Dewar made a brass chamber that he enclosed in another chamber to keep the palladium at its desired temperature. He evacuated the air between the two chambers, creating a partial vacuum to keep the temperature of the contents stable. Dewar refused to patent his invention; this allowed others to develop the flask using new materials such as glass and aluminium, and it became a significant tool for chemical experiments and also a common household item.
Spinoff is a NASA publication featuring technology made available to the public. Since 1976, NASA has featured an average of 50 technologies each year in the annual publication, and Spinoff maintains a searchable database of these technologies. When products first spun off from space research, NASA presented a black and white report in 1973, titled the "Technology Utilization Program Report". Because of interest in the reports, NASA decided to create the annual publications in color. Spinoff was first published in 1976, and since then, NASA has distributed free copies to universities, the media, inventors and the general public. Spinoff describes how NASA works with various industries and small businesses to bring new technology to the public. As of 2016, there were over 1,920 Spinoff products in the database dating back to 1976.
Again, in countries like Nigeria where the Same-Sex Marriage (Prohibition) Act, 2013 (SSMPA) "prohibits a marriage contract or civil union entered into between persons of the same sex...", lesbian, gay, bisexual, asexual and transgender people who are raped and targeted do not have the protection of the police and cannot report rape crimes done to them, as the police are likely to legitimize the abuse. Reports of corrective rape are cloaked in stigma and embarrassment so they remain largely underreported. Apart from this being a violation of the fundamental right to protection as stated in the Violence Against Persons (Prohibition) Act 2015, this sexual discrimination poses a threat to the general health of homosexual people who are victims of rape as they also fear the intolerance and disregard from medical providers, leaving them susceptible to STIs and HIV.
=== Genetics === Happiness is partly genetically based. Based on twin studies, 50 percent of a given human's happiness level is genetically determined, 10 percent is affected by life circumstances and situation, and a remaining 40 percent of happiness is subject to self-control. Whether emotions are genetically determined or not was studied by David Lykken and Auke Tellegen. They found that up to 80% of the variance in long-term sense of well-being among Minnesotan twins separated at birth was attributable to heredity. The remaining theoretical 20%, however, still leaves room for significant change in thoughts and behavior from environmental/learned sources that should not be understated, and the interpretation of variance in twin studies is controversial, even among clinical psychologists. Individual differences in both overall Eudaimonia, identified loosely with self-control, and in the facets of eudaimonia are inheritable. Evidence from one study supports 5 independent genetic mechanisms underlying the Ryff facets of this trait, leading to a genetic construct of eudaimonia in terms of general self-control, and four subsidiary biological mechanisms enabling the psychological capabilities of purpose, agency, growth, and positive social relations.
In 1959, Adolf Butenandt identified the first intraspecific chemical signal (bombykol) from the silk moth, Bombyx mori, with material obtained by grinding up 500,000 moths. The same year, Karlson and Lüscher proposed the term 'pheromone' to describe this type of signal. Also in 1959, Gottfried S. Fraenkel also published his landmark paper, "The Raison d'être of Secondary Plant Substances", arguing that plant secondary are not metabolic waste products, but actually evolved to protect plants from consumers. Together, these papers marked the beginning of modern chemical ecology. In 1964, Paul R. Ehrlich and Peter H. Raven coauthored a paper proposing their influential theory of escape and radiate coevolution, which suggested that an evolutionary "arms-race" between plants and insects can explain the extreme diversification of plants and insects. The idea that plant metabolites could not only contribute to the survival of individual plants, but could also influence broad macroevolutionary patterns, would turn out to be highly influential. However, Tibor Jermy questioned the view of an evolutionary arms race between plants and their insect herbivores and proposed that the evolution of phytophagous insects followed and follows that of plants without major evolutionary feedback, i.e. without affecting plant evolution. He coined the term sequential evolution to describe plant-insect macroevolutionary patterns, which emphasizes that selection pressure exerted by insect attack on plants is weak or lacking.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.